Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Diverse opinions on RELX ahead of results this week, with an Investec 'buy' just in favour

Investec's analysts said they see a “nice buying opportunity" ahead of the full-year numbers, due on February 15
However, the analysts at BarCap downgraded their recommendation on RELX to ‘equal-weight’ from ‘overweight’

RELX PLC (LON:REL) edged higher today ahead of the information and analytics company's full year results later this week, with some bullish comments from Investec Securities countering a downgrade in rating by Barclays Capital.

In late morning trading, the FTSE 100-listed shares were 0.3%, or 5p higher at 1,487p.

READ: RELX Group reports continued underlying revenue growth, reaffirms full year outlook

In a note to clients, the analysts at Investec reiterated a ‘buy’ rating on RELX shares, with a price target of 1,900p, and said they see a “nice buying opportunity" ahead of the numbers, due on February 15.

The analysts added: “We unashamedly focus on the equity investment case (not bond arguments), with an attractive broad shift to higher value/quality data analytics and US skew.

“Valuation is top end for UK Media, cheap for a high-quality data business; though share price falls bring the B2B premium spread in materially.”

However, the analysts at BarCap downgraded their recommendation on RELX to ‘equal-weight’ from ‘overweight’ having reduced their sum-of-the-parts based price target to 1,600p due to a modest earnings downgrade, and slightly lower multiples across the group due to peer de-rating.

They said: “RELX did rerate on a relative basis: reliable stories were scarce. They have now given this back. But we feel that further relative rerating would require more confidence on this issue. And that is what we now struggle to see in the short term.”

RELX has an “uncertainty problem”

The analysts also noted that RELX has an “uncertainty problem” which it thinks changes the story, which has been about reliability for the last five years.

They said: “The uncertainty comes in Scientific, Technical and Medical (STM) (33% of revenues; 40% of EBITA), where a protracted negotiation with a consortium of German universities is raising question marks about future journals' growth.

“We had previously thought there would be a resolution to this negotiation and the issue would start to drift away. We have changed our mind after speaking to a handful of industry consultants.”

The analysts added:” While the comments varied, the overall impression was that the situation will drag on, and it will not be easy in the next 6-9 months to build confidence on future growth at RELX's STM.”

View full REL profile View Profile

RELX PLC Timeline

Related Articles

April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006
Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.
Students in a class
August 27 2018
The company is gaining traction in Asia where people are looking to take language courses to work or study internationally

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use